117.62
0.15%
0.18
Handel nachbörslich:
117.62
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
0.02%
515.30
|
515.20 | 498.80 | 452.70 | 420.40 |
Cost Of Revenue |
11.76%
7.50
|
8.50 | 11.20 | 11.50 | 8.50 |
Gross Profit |
0.22%
507.80
|
506.70 | 487.60 | 441.20 | 411.90 |
Operating Expenses
|
14.62%
408.50
|
356.40 | 346.40 | 367.60 | 526.10 |
Interest Income/Expense |
0.00%
1.10
|
1.10 | 1.10 | 1.30 | 1.10 |
Benefits Costs and Expenses |
51.67%
480.80
|
317.00 | 383.20 | 331.10 | 523.70 |
Costs And Expenses |
14.00%
416.00
|
364.90 | 357.60 | 379.10 | 534.60 |
Operating Income/Loss |
33.93%
99.30
|
150.30 | 141.20 | 73.60 | -114.20 |
Nonoperating Income/Loss |
235.28%
-64.80
|
47.90 | -25.60 | 48.00 | 10.90 |
Income/Loss From Continuing Operations Before Tax |
82.59%
34.50
|
198.20 | 115.60 | 121.60 | -103.30 |
Income Tax Expense/Benefit |
117.62%
-8.90
|
50.50 | 32.50 | 26.10 | -26.70 |
Income/Loss From Continuing Operations After Tax |
70.62%
43.40
|
147.70 | 83.10 | 95.50 | -76.60 |
Net Income/Loss
|
70.62%
43.40
|
147.70 | 83.10 | 95.50 | -76.60 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
49,800%
99.80
|
0.20 | 97.90 | 97.60 | 97.10 |
Diluted Average Shares |
25,800%
103.60
|
0.40 | 101.10 | 100.20 | 97.10 |
Basic Earnings Per Share |
71.52%
0.43
|
1.51 | 0.85 | 0.98 | -0.79 |
Diluted Earnings Per Share |
71.23%
0.42
|
1.46 | 0.82 | 0.95 | -0.79 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):